Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VD's Model Portfolio & Discussion Thread -- Ignore unavailable to you. Want to Upgrade?

To: Vector1 who wrote (6257)	1/14/1999 2:15:00 AM
From: Pseudo Biologist	Read Replies (1) \| Respond to of 9719

Remembering a great, but not "celebrated" enough, pick (MLNM): Message 6503165 I wonder if you had a chance to attend the MLNM presentation at H&Q (or is it tomorrow?). The stock has certainly taken off in the last month or so. The Bayer deal, among others, still has people talking. This month's issue of Nature Biotechnology (page 16) carries a little article on "platform companies." Interesting quotes from INCY, ARQL, and MLNM, with the first one (Whitfield) NOT anxious to tackle the risks associated with drug development MLNM's Levin OTOH does want (MLNM) to be more than a gene and target company PB

To: Vector1 who wrote (6257)	1/14/1999 2:55:00 PM
From: Steve Lokness	Read Replies (1) \| Respond to of 9719

Vector1; I thought ABSC had a machine delivered? Is their own machine up and running? Will ABSC do any of their own targets or when they find a hit, will they then partner out? Do each of the machines have their own libraries? Does ABSC sell any libraries along with their machines? Thanks; Steve